Full Press Release Details
("Midatech" or the "Company")
Midatech Pharma PLC (AIM: MTPH.L; Nasdaq:
MTP), the R&D company focused on delivering innovative oncology and rare disease products to patients, is pleased to announce
that all resolutions were passed at the Annual General Meeting held earlier today.
For more information, please contact:
(UK) Limited (Nominated Adviser and Broker)
Emma Earl (Corporate Finance)
Limited (Financial PR and UK Investor Relations)
/ Tim Metcalfe / Heather Armstrong
Westwicke Partners (US Investor Relations)
Tel: +1 339 970 2843
Email: chris.brinzey@westwicke.com
Midatech Pharma PLC (dual listed on LSE
AIM: MTPH; and NASDAQ: MTP) is an R&D company focused on Making Medicines Better' by improving delivery of drugs
in the body. The Company combines existing medications with its proprietary and innovative drug delivery technologies to
provide compelling oncology and rare disease products that have the potential to powerfully impact the lives of patients undergoing
treatment for life threatening diseases.
The Company has developed three in house
technology platforms, each with its own unique mechanism to improve delivery of medications to sites of disease. All of the Company's
technologies are into the clinic:
Midatech's headquarters and R&D facility
is in Cardiff, UK, and manufacturing operation in Bilbao, Spain. For more information please visit www.midatechpharma.com